Founder, The Cannabis Council Eastern Shore Innovation Center

Slides:



Advertisements
Similar presentations
The BECOTEPS White Paper BECOTEPs Science Writer Mary Brennan Senior Lecturer in Food Marketing School of Agriculture, Food and Rural Development, University.
Advertisements

Pharmaceutical Sciences Presented by [Insert your name & title here] [Insert name of your PSMO]
The Medical Marijuana Maze Chapter One: Introduction Nancy E. Marion Copyright © 2014 Nancy Marion. All rights reserved.
#279 Cannabis For Symptom Control By: Kelsey Jungels.
Medical Marijuana in the United States A Brief History SW IALEP Chapter Glendale, Arizona February 8, 2011.
Stages of drug development
Selection Sourcing Structure Standardization Safety Substantiation
Clinical Research Training
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Data Infrastructures Opportunities for the European Scientific Information Space Carlos Morais Pires European Commission Paris, 5 March 2012 "The views.
1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.
For Pain or Not for Pain: Methadone Madness
AAMC Council of Faculty and Academic Societies (CFAS) Pamela N Peterson, MD MSPH Associate Professor of Medicine Kevin Lillehei, MD Professor and Chair,
Baltimore Buprenorphine Initiative Advancing Recovery Project Baltimore City, Maryland January 14, 2010.
Collegiate Cancer Council C C C The Founders Our Council.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.
Copyright 2012 Delmar, a part of Cengage Learning. All Rights Reserved. Chapter 9 Improving Quality in Health Care Organizations.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Medical Cannabis in Maryland Presentation to University of Maryland Medical School Quarterly Meeting October 8, 2015 by Deborah Miran Commissioner Maryland.
Medicinal Cannabis Shelly Van Winkle RN
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
Preventing drug diversion: Principles and concepts International Pain Policy Fellowship August 7, 2012 David E. Joranson Distinguished Scientist, Founder.
For Internal Use Only NBRC4Y
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.9: Unit 9: The evolution and reform of healthcare in the US 1.9c: Quality Indicators.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
Abuse-Deterrent Opioids: FDA’s Role and Emerging Challenges Jeanne Ireland Principal, Ireland Strategies, LLC 2015 CWAG Annual Meeting.
دکترارتین کمالی ثابتی ( متخصص پزشکی قانونی ومسمومیتها )
Unravelling addictions and brain reward systems Abuse liability / misuse of medication Prof T F Meert, PhD., PhD. Senior Director External Innovation,
Cannabis Stock Market The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce,
Steven Cantor Life Medical Technologies, Inc. Steven A. Cantor and His Efforts in Cardiovascular Disease Treatment.EECP Treatment for Patients with Angina.
The AMA: Reducing Opioid Abuse in America Patrice A. Harris, MD, MA Board Chair American Medical Association September 2016.
Legalize it: Medicinal Marijuana Caitlin Moran Tuesdays 3:30pm-5:30pm Dr. S Goldberg.
Off-label Use.
ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.
Legal and Regulatory Issues in Pain Management
*Risk Evaluation and Mitigation Strategy
World Health Organization
Cannabis in medicinal use
Opioid Prescribing CAPT Thomas Weiser, MD, MPH Medical Epidemiologist
Medical Cannabis Dr. Andrea Burry MSc MD CCFP
Bigger. Bolder..
Properties of Cannabis
Lessons Learned Through HBD: The Regulator’s View - US FDA
Treat Back Pain with CBD
Addiction and the Opioid Crisis: HHS Update
CANNABIS AND CANNABINOIDS: THE CONUNDRUM
The Myths and Realities of the Opioid Epidemic AMERSA November 3, 2017
Pharmaceutical- vs Dispensary-Sourced Cannabinoids
Implications of cannabis international regulation and its impact on medicinal use Dra. Leticia Cuñetti June 2018.
Indispensable, adequately provided and not unduly restricted
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Opioids in Butte County
Turning the Tide in Health Care Starts with Chronic Disease
Medical Research Funding and Regulation Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institutes of Health.
Introduction to TransCelerate
Clinical Cannabis Interprofessional Education: Program Development and Provider Knowledge Cameron, M.H. 1,2 & Jones, K.D.3,4 1. VA Portland Health Care.
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
collaboration giving community 2018 HOUSTON OPIOID SUMMIT
Dr Manisha Shridhar Regional Advisor WHO-SEARO
The Evolving Role Of Medical Affairs (MA)
Industrial Hemp Primer
BioCapital Europe 2019, Amsterdam
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Access to Cannabis for Medicinal and Research Purposes
PHARMACOVIGILANCE SYSTEM
Presentation transcript:

Founder, The Cannabis Council Eastern Shore Innovation Center Standardization of Method The requirement for credible investigation Maryland’s Medical Cannabis Program BUDTech Summit – UMD, Baltimore Barry F. Pritchard Founder, The Cannabis Council Eastern Shore Innovation Center Cambridge, MD September 22, 2017

THC Discovered in 1964 THC was discovered by Dr. Raphael Mechoulam in Israel Until the discovery and isolation of Delta-9 tetrahyrdrocannabinol, scientists did not understand what caused the psychoactive effect in Cannabis. Since then, multiple components including THC, CBD, CBC, CBG, not to mention terpines and flavonoids have been identified within the cannabis plant. Raphael Mechoulam - Father of Cannabinoid Research http://www.beyondthc.com/wp-content/uploads/2012/07/eCBSystemLee.pdf Delta-9 Tetrahydrocannabinol

Agenda Importance of the Standardization of Methods Cannabis: History - Prohibition Lack of peer reviewed clinical research data The Cannabis Council Importance of the Standardization of Methods – Required for credible investigation PAT – Process Analytical Technology MD Medical Cannabis Program – The framework for scientific endeavor

Our Mission Statement: To support the medical cannabis and industrial hemp industries in their effort to provide safe, well-characterized agriceuticals and sustainable materials.

How we support the community? Public Awareness Forums - Inform the masses a. Prohibition - Ongoing perception propagation b. Benefits of the potential pharmaceuticals and sustainable by-product materials c. Regulatory controls - Ensuring safe products

How we support the community? Technical Symposia - Speak to the choir in support of research focused advocacy groups a. Need for SME to join to fray – A call to action for industry participation b. Bridge the technical communication gap - Underground vs. Classically trained c. What is PAT? - The case for method standardization d. Regulated market - The requirement for credible investigation e. Promoting collaboration – find a common language

How we support the community? Workforce development - SunX site in Cambridge a. Training – cannabis industries b. Employee retention – Career development programs c. Support for entrepreneurs

Historical lack of standard methods and processes Opportunity for making a difference The Challenge: With the rules for testing cannabis varying from state to state, each laboratory determining its own testing methods, the difficulties is the procurement of high-quality reference materials and the lack of common scientific term usage, the industry has little likelihood of achieving uniformity, and by extension, credibility. The Evidence of the problem: Enables the common practice of results shopping The Solution: Good Documentation – Disciplined effort Commitment to process development

Critical Process Parameters What this looks like in practice: Cannabinoid extraction, isolation and formulation Science or Art? Process analytical technology (PAT) has been defined as a mechanism to design, analyze, and control pharmaceutical manufacturing processes through the measurement of Critical Process Parameters Benefits: Improve efficiency Reduce costs Increase understanding of process Reproducibility!

THC Discovered in 1964 THC was discovered by Dr. Raphael Mechoulam in Israel Until the discovery and isolation of Delta-9 tetrahyrdrocannabinol, scientists did not understand what caused the psychoactive effect in Cannabis. Since then, multiple components including THC, CBD, CBC, CBG, not to mention terpines and flavonoids have been identified within the cannabis plant. Raphael Mechoulam - Father of Cannabinoid Research http://www.beyondthc.com/wp-content/uploads/2012/07/eCBSystemLee.pdf Delta-9 Tetrahydrocannabinol

Cannabis as WHOLE Medicine FACT: Currently, Cannabis is listed as a SCHEDULE 1 drug federally. Schedule 1 drugs are substances that have a high potential for abuse AND no currently accepted medical treatment use. FACT: Cannabis’ singular cannabinoid THC has been synthesized and mass produced as the SCHEDULE 3 drug (Dronabinol ) (Marinol) used and proven to have moderate success in treating nausea, vomiting, anxiety, pain mitigation and insomnia in terminal patients. QUANDRY: Recent research indicates that WHOLE PLANT Cannabis derivatives can be MORE effective in treating a variety of conditions than isolated cannabinoids. Whole plant derivatives work as a natural modulator and with higher levels of efficacy due to a phenomenon expressed as “The Entourage Effect.” CBD in particular, has been found to down regulate the psychoactive properties of THC. Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity AM J HOSP PALLIAT CARE August 2011 28: 297-303, first published on March 28, 2011

One more thing: THE case for Cannabis Cannabis lethal dose risk - Essentially Zero* *It would take 150lb man to smoke 1500 pounds in 15 minutes. 2013 Data from CDC on drug induced deaths Total – 43,982 Prescription analgesics – 16,235 Heroin - 6,235 Cannabis – 0 Evidence of Decreased Opioid Overdose Mortality in U.S.: “States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate.” (Bachhuber, M.A. (2014) Journal American Medical Association)

Summary SME call to arms Take the time to bridge the divide Cannabis – The gateway from dope? Volunteer - Vote Hemp, WeCANN, TCC

Thank you for your attention! Acknowledgements for with – permission use of materials: WeCANN – MD MD Medical Cannabis Commission AOCS – American Oil Chemist’s Society Barry F. Pritchard, MBA bpritchard@thecannabiscouncil.org